On April 14, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place April 17–22 in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The research that Tempus is presenting at this year’s AACR (Free AACR Whitepaper) annual meeting underscores the scale and real-world impact of Tempus’ multimodal dataset and AI-enabled diagnostic solutions," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "Across these studies, our researchers are uncovering clinically relevant insights that not only deepen our understanding of tumor biology, but also have the potential to transform how cancer is diagnosed and treated. This work is a product of our ongoing commitment to advancing the field of oncology and, ultimately, to improving outcomes for the patients we serve."

Tempus will host an Exhibitor Spotlight Theater session on Monday, April 20, 2026, from 10:00–11:00 AM PST in Theater B of the Sails Pavilion. In "Beyond the Pilot: Scaling Multimodal AI and Lab-in-the-Loop for Breakthrough R&D," Sasser and Neil Bence, PhD, Senior Vice President of the Protein Homeostasis Thematic Research Center at Bristol Myers Squibb, will explore how combining deep molecular insights with high-throughput Lab-in-the-Loop functional screening can accelerate breakthroughs.

Tempus research highlights presented at this year’s conference include:

Co-occurrence of gene fusions and microsatellite instability (MSI) defines a clinically distinct subtype of colorectal cancer
Sunday, April 19, 2026, 2:00 – 5:00 PM PT
Section 20
Investigation into the co-occurrence of gene fusions and microsatellite instability (MSI) in 30,884,099 colorectal cancer patients revealed that clinically relevant fusions are significantly enriched in MSI versus MSS tumors (6.2% vs. 2.2%). These findings suggest that the clinical impact of gene fusions is mediated by MSI status, defining a distinct molecular subtype of colorectal cancer that may influence therapeutic stratification.
Oral Presentation: Real-world evidence of KMT2C mutation as a biomarker of sensitivity to platinum-based therapy in solid cancers
Monday, April 20, 2026, 2:30 – 4:30 PM PT
Room 14-Mezzanine Level – Convention Center
Researchers leveraged Tempus Lens to define a real-world cohort of 143,961 patients with solid tumors from the Tempus multimodal database. They sought to determine if KMT2C mutations are a biomarker for sensitivity to platinum-based chemotherapy (PBC). Their analysis revealed that patients with KMT2C mutations had significantly improved real-world overall survival (rwOS) after PBC treatment compared to patients without the mutation (19.6 vs. 16.7 months). The survival benefit was most significant in colorectal cancer (CRC), where patients with the mutation had a median rwOS of 51.0 months versus 25.3 months for those without. These findings, validated in the AACR (Free AACR Whitepaper) Genie dataset, support KMT2C as a predictive biomarker for platinum response—particularly in CRC and GI cancers—with laboratory studies underway to clarify mechanisms.
Analysis of RNA expression of 47 cell surface proteins in real-world small cell lung cancer patients
Tuesday, April 21 9:00 AM – 12:00 PM PT
Section 46
The research team performed an exploratory analysis of 56 cell surface proteins (CSPs) in 1,353 small cell lung cancer (SCLC) patients to identify differential expression patterns across subtypes, disease stages, and treatment statuses. Leveraging Tempus xT DNA-seq and xR RNA-seq data, the study identified subtype-specific expression.
Machine learning predicts retained retinoblastoma (Rb) function in real-world small cell lung cancer patients
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 46
To challenge the long-held belief that the retinoblastoma (RB) tumor suppressor is always inactive in small cell lung cancer (SCLC), the research team developed a machine learning model to predict RB function. Using genomic (Tempus xT) and transcriptomic (Tempus xR) data from a real-world cohort of approximately 1,400 SCLC patients, the model found that nearly 30% of patients with RB1 genomic alterations still showed evidence of RB function transcriptionally.
Immune-related RNA-seq biomarker-based clustering reveals heterogeneous immunotherapy responses and guides subtype-specific strategies in metastatic NSCLC
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 42
Patients with metastatic non-small cell lung cancer (mNSCLC) respond variably to first-line immunotherapy plus chemotherapy, yet the underlying immune biology driving these differences remains poorly understood. In a real-world cohort of 2,235 mNSCLC patients from the Tempus database, RNA-seq-based unsupervised clustering using immune markers identified four biologically distinct immune subtypes.
Validation of HER2, TROP2, and NECTIN4 IHC prediction algorithms for the ADC MATCH trial
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 6
To facilitate patient selection for the ADC MATCH clinical trial, investigators validated RNA-seq algorithms designed to identify patients likely to test positive for HER2, TROP2, and NECTIN4 via immunohistochemistry (IHC).
Detection of rare oncogenic fusions through concurrent DNA and RNA next-generation sequencing in a pan-cancer clinical setting
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 49
By retrospectively analyzing de-identified records from 74,182 patients with advanced cancer, this study quantified the clinical benefit of concurrent DNA and RNA testing for identifying rare oncogenic fusions.
Learn more about Tempus at AACR (Free AACR Whitepaper) Annual Meeting 2026.

(Press release, Tempus, APR 14, 2026, View Source [SID1234664375])

On April 14, 2026 MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, reported it will host a conference call and webcast to present 3-year data from the long-term follow-up of patients in the Phase 1 study of AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX) on Thursday, April 16, 2026, at 8:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will include:

Three-year data from the long-term follow-up of the patients in the open-label Phase 1 AQUAx clinical study.

This data will include:

PRO Xerostomia Questionnaire (XQ) data out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts
Objective Unstimulated Whole Saliva Flow Rate (UWSFR) data out to 3 years
Full cohort data, as well as individual patient data out to 3 years for both the XQ and UWSFR

Study Investigator discussion of disease burden, patient experience, and treatment administration

Commercial opportunity

A question-and-answer session will follow the formal presentation.

To register and attend the event, please click here.

A live webcast of the call, as well as a replay, will be available on the Investors page of the Company’s website at www.investors.meiragtx.com/.

About the Phase 1 AQUAx Clinical Trial

The Phase 1 AQUAx clinical trial is an open-label, non-randomized, dose escalation trial designed to evaluate the safety of MeiraGTx’s investigational gene therapy AAV-hAQP1 when administered via Stensen’s duct to one or both parotid glands in patients who have been diagnosed with grade 2 or 3 radiation-induced xerostomia and who have remained cancer-free for at least five years (or at least two years if HPV+) after receiving radiation treatment for head and neck cancer. Primary endpoint of the trial is safety, with efficacy endpoints including patient-reported measures of xerostomia symptoms and the evaluation of the change in parotid gland salivary output after treatment with AAV-hAQP1. The 12-month data have been released and presented publicly. Patients treated in the Phase 1 AQUAx study are followed for 5 years after the one-time administration of AAV-hAQP1.

(Press release, MeiraGTx, APR 14, 2026, View Source [SID1234664391])

On April 14, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, reported that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place in Toronto on April 21-22, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During this investor presentation, the Company will provide a corporate update as well as latest MDNA113 preclinical data from the 2026 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper). More details are as follows:

Date: Tuesday, April 21, 2026
Time: 3:00 p.m. Eastern Time
Location: Metro Toronto Convention Centre, Toronto
Webcast Link: https://event.summitcast.com/view/7Mc8ivebFGUgA8YD45rSGK/UpbJ5d5vehkPikKiwCUsv6

Webcast and replay information for this event will also be available on the Investor Relations section of Medicenna’s website at ir.medicenna.com. The replay will be available for 90 days.

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings. For more information, please visit: bloomburton.com/conference.

(Press release, Medicenna Therapeutics, APR 14, 2026, View Source [SID1234664359])

On April 14, 2026 Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, reported it will release groundbreaking new data at the 2026 Annual American Association for Cancer Research (AACR) (Free AACR Whitepaper) meeting in San Diego, California. A major highlight of this year’s conference participation is the first clinical data disclosure from the MYTHIC Study (NCT04855656), a Phase I trial evaluating the combination of Debiopharm’s WEE1 inhibitor, zedoresertib (Debio 0123), with the PKMYT1 inhibitor lunresertib (Debio 2513) in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations. The oral presentation on April 19th 2026 will be given by Dr. Timothy A. Yap, a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center and Principal Investigator of the MYTHIC study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Comprehensive pre-clinical results will also be presented for the MultiLINK ADC Technology Suite, showcasing the potential of novel dual payload antibody drug conjugates (ADCs) to enhance therapeutic efficacy. Two translational research posters will also be featured: the first highlighting the development of a Deep Learning-based "virtual" Cyclin E1 biomarker to predict protein overexpression in gynecological malignancies from H&E slides; the second unveiling how multiplexed spatial profiling and 3D cluster analysis are being used to reconcile RNASeq, mass spectrometry, and IHC data to refine therapeutic strategies for HER3 bispecific antibody and ADC programs.

"The first clinical results of the MYTHIC study mark an important milestone for the program. Early data readouts suggest strong synergistic activity between zedoresertib and lunresertib, with tumor regressions observed in patients," explained Esteban Rodrigo Imedio, Executive Medical Director, Oncology, Debiopharm

"Dual payload ADC technology has the potential to be a game changer for cancer patients. As patients need innovative solutions for hard-to-treat cancers, we hope that our dual payload research using MLINK Duo ADC linker technology will help us reshape how complex cancers are targeted and treated," expressed Antoine Attinger, Director, Translational Pharmacology, Debiopharm.

SESSION DETAILS

Session Type: Clinical Trials Plenary Session
AACR 2026 Oral Presentation

Debiopharm Compound

Title

Presenter

– Sun, April 19
– Time: 2:00 PM

– Hall H

zedoresertib (Debio 0123) & lunresertib (Debio 2513)

First data disclosure of the Phase I trial of the first-in-class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations

Dr. Timothy A. Yap, Medical Oncologist, University of Texas MD Anderson Cancer Center, Houston, TX

Session Title: Antibody Drug Conjugates and Linker Engineering 1
AACR 2026 Poster Presentation

Debiopharm Technology

Title

Author

– Mon, April 20
– Display: 9:00 AM – 12:00 PM
– Poster #: 1683
– Section: 12

MLINK Duo

Enhancing therapeutic efficacy and overcoming resistance with a novel dual payload antibody drug conjugate technology

Antoine Attinger et al., Translational Medicine,
Debiopharm International SA, Lausanne

Session Title: Digital Pathology 3
AACR 2026 Poster Presentation

Debiopharm Program

Title

Author

– Tue, April 21
– Display: 9:00 AM – 12:00 PM
– Poster #: 4155
– Section: 3

zedoresertib (Debio 0123)

Development of a virtual Cyclin E1 biomarker using Deep Learning from H&E slides for predicting Cyclin E1 overexpression in gynecological malignancy

Jeannette Fuchs et al.,
Translational Medicine, Debiopharm International SA, Lausanne

Session Title: Molecular Targets 2
AACR 2026 Poster Presentation

Debiopharm Program

Title

Author

– Tue, April 21
– Display: 2:00 PM – 5:00 PM
– Poster #: 5738
– Section: 13

HER3 ADCs

Beyond bulk: Resolving RNASeq/mass spectrometry/IHC discrepancies with multiplexed spatial profiling and 3D cluster analysis to refine HER3 (bs)Ab and (bs)ADC therapeutic strategies

Jeannette Fuchs et al.,
Translational Medicine, Debiopharm International SA, Lausanne

ABOUT DNA DAMAGE REPAIR (DDR)

When cells have damaged DNA, they must undergo a repair process known as DDR to survive. Cancer cells rely heavily on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, ultimately activating a programmed cell death process. DDR inhibitors such as zedoresertib (Debio 0123), Debiopharm’s WEE1 inhibitor, are currently being investigated in clinical and preclinical studies.

ABOUT PKMYT1 INHIBITION

Lunresertib (Debio 2513) is a first-in-class, oral PKMYT1 inhibitor designed to exploit specific genetic vulnerabilities in solid tumors, such as CCNE1 amplification. By targeting PKMYT1, the drug induces synthetic lethality, preventing cancer cells from repairing DNA damage and forcing them into programmed cell death. As the most advanced PKMYT1 inhibitor in clinical development, lunresertib has shown encouraging proof-of-concept results both as monotherapy and in combination therapies within the ongoing MYTHIC trial.

(Press release, Debiopharm, APR 14, 2026, View Source [SID1234664376])

On April 14, 2026 CERo Therapeutics Holdings, Inc., (OTCQB: CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, reported it has dosed the third patient in the second cohort (sixth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies. The patient had MDS that evolved to acute myeloid leukemia (AML). The trial was recently expanded to include earlier forms of MDS and myelofibrosis (MF).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study continues to progress in accordance with protocol, with patients undergoing monitoring for safety, pharmacokinetics, pharmacodynamics, and clinical activity. With more than seven days of follow-up completed after the most recent infusion, CERo continues to evaluate key endpoints across dose levels as it advances through dose escalation.

As previously presented at the February Tandem Meetings in Salt Lake City, CER-1236 has demonstrated no reported cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade, and no dose-limiting toxicities observed during the 28-day assessment window. Investigators also reported in vivo cell expansion, with peak levels observed between days 10 and 14 following infusion. Additionally, as previously reported, a single patient with inv(3) AML who received four CER-1236 infusions over five months at the lowest dose level achieved 72 consecutive days of platelet transfusion independence. These findings informed the protocol amendment expanding enrollment into patients with MDS and MF.

Robert Sikorski, M.D., Ph.D., CERo Chief Medical Officer, stated, "This is the third patient in the cohort, and completion of the dose-limiting toxicity evaluation period may enable further dose escalation in accordance with the protocol. We continue to evaluate the safety profile and early clinical data as CER-1236 is studied in patient populations with significant unmet need."

The first-in-human, multi-center, open-label Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236. The trial was initially focused on AML patients, including those with relapsed/refractory disease, measurable residual disease, or newly diagnosed TP53-mutated AML, and has since expanded to include transfusion-dependent MDS (TD-MDS), high-risk MDS (HR-MDS), and post-JAK inhibitor myelofibrosis (MF). Primary endpoints include safety and tolerability, while secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD).

CERo Chief Executive Officer Chris Ehrlich added, "Dosing our sixth patient and expanding into MDS represents continued execution of the CERTAIN-T trial and an important milestone for CERo. We believe CER-1236 has the potential to address multiple hematologic malignancies, and we look forward to further advancing the study and sharing additional clinical updates."

(Press release, Cero Therapeutics, APR 14, 2026, View Source [SID1234664392])